The IP focuses on pairing oncolytic viruses with engineered adoptive cell therapies, such as CAR-T and CAR-NK cells, to enhance their anti-tumor capabilities within challenging tumor microenvironments. The significance of this IP lies in its ability to address several key challenges in cancer immunotherapy. By engineering the oncolytic virus to express T cell activating cytokines and modifying T or NK cells to interrupt inhibitory pathways while inserting genes regulated by virus-expressed factors, this approach aims to improve the safety and efficacy of engineered cell therapies. Additionally, the use of SynNotch technology for regulated gene expression is a novel strategy for enhancing therapeutic specificity and activity. The stage of development for this IP is currently at the conceptual and prototype phase, with further work planned for validation and refinement. The IP offers compelling advantages over existing methods. Its safety, specificity, and activity (coupled with the ability to regulate cell function using oncolytic viruses) appeal to biotechnology and pharmaceutical companies seeking innovative cancer therapies. The potential applications of this technology extend beyond CAR expression, paving the way for future developments in targeted cancer immunotherapy and gene regulation.